Guardant Health, Inc.

Equities

GH

US40131M1099

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
20.63 USD +14.87% Intraday chart for Guardant Health, Inc. +15.06% -23.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer CI
Transcript : Guardant Health, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 01:00 PM
Piper Sandler Cuts Price Target on Guardant Health to $30 From $40, Maintains Overweight Rating MT
UBS Adjusts Guardant Health Price Target to $32 From $45, Maintains Buy Rating MT
Canaccord Genuity Adjusts Price Target on Guardant Health to $45 From $50, Maintains Buy Rating MT
Guardant Health Q4 Adjusted Loss Narrows as Revenue Rises MT
Transcript : Guardant Health, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (GH) GUARDANT HEALTH Posts Q4 Revenue $155.1M, vs. Street Est of $150.8M MT
Guardant Health, Inc. Provides Earnings Guidance for the Year 2024 CI
Guardant Health, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Guardant Health, Inc. Announces Resignation of Mr. Samir Kaul as Member of the Board and as Member of the Compensation Committee of the Board CI
Goldman Sachs Cuts Price Target on Guardant Health to $37 From $43, Maintains Buy Rating MT
Transcript : Guardant Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM
Guardant Health Reports Preliminary Q4 Revenue MT
EDX Medical maintains confident outlook; implements biopsy tests AN
Guardant Health Teams Up With Hikma Pharmaceuticals to Offer Cancer Diagnostics in Middle East, North Africa MT
Guardant Health Names Terilyn Juarez Monroe as Chief People Officer MT
Guardant Health, Inc. Announces Executive Changes CI
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
Guardant Health Reports Tentative Date for US FDA Advisory Panel Review of Shield Blood Test MT
Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test CI
Guardant Health Insider Sold Shares Worth $152,954, According to a Recent SEC Filing MT
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities CI
Transcript : Guardant Health, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-28-2023 09:30 AM
North American Morning Briefing : Caution -2- DJ
Chart Guardant Health, Inc.
More charts
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
20.63 USD
Average target price
41.76 USD
Spread / Average Target
+102.45%
Consensus
  1. Stock
  2. Equities
  3. Stock Guardant Health, Inc. - Nasdaq
  4. News Guardant Health, Inc.
  5. Craig-Hallum Initiates Guardant Health at Buy With $88 Price Target